Palisade Bio (NASDAQ:PALI) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research began coverage on shares of Palisade Bio (NASDAQ:PALI) in a research report report published on Wednesday, MarketBeat reports. The brokerage issued an outperform rating and a $7.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the company. Clear Str raised Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Stifel Nicolaus started coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, HC Wainwright started coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Palisade Bio currently has an average rating of “Moderate Buy” and a consensus target price of $10.20.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $1.82 on Wednesday. The stock’s fifty day moving average price is $1.81 and its two-hundred day moving average price is $1.83. Palisade Bio has a one year low of $0.53 and a one year high of $2.64. The firm has a market cap of $301.90 million, a price-to-earnings ratio of -0.86 and a beta of 1.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd raised its stake in Palisade Bio by 53.8% during the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after buying an additional 7,584 shares during the last quarter. Cetera Investment Advisers purchased a new position in Palisade Bio during the fourth quarter valued at $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio during the fourth quarter valued at $26,000. Virtu Financial LLC purchased a new position in shares of Palisade Bio in the fourth quarter worth $28,000. Finally, Atom Investors LP purchased a new position in shares of Palisade Bio in the fourth quarter worth $33,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.